High-dose chemotherapy: is it standard management for any common solid tumor?

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• High-dose chemotherapy (HDCT) with stem-cell support is based on observed dose-response relationships and retrospective data suggesting dose intensity impacts patient outcomes.
• Advances in hematopoietic growth factors and stem-cell technology have made HDCT feasible and safer to evaluate.
• Despite feasibility, the actual benefit of HDCT in solid tumors remains a subject of investigation.

Purpose of the Study:

• To review the evidence for dose-response relationships of chemotherapeutic agents.
• To summarize results from non-randomized and randomized trials of HDCT with stem-cell support for breast, ovarian, and small cell lung cancers.
• To assess the current evidence for establishing HDCT as a standard treatment for these cancers.

Main Methods:

• Examination of evidence for dose-response relationships in standard chemotherapy.
• Review and summarization of non-randomized and randomized clinical trial data for HDCT.
• Analysis of existing data to draw conclusions on the standard of care.

Main Results:

• Currently, insufficient randomized trial data exists to support HDCT as a standard treatment for breast, ovarian, or small cell lung cancer.
• Apparent benefits in Phase II trials may be attributable to patient selection and stage shifts.
• Many relevant randomized trials are ongoing, with final results pending for definitive benefit quantification.

Conclusions:

• HDCT cannot be considered a standard treatment for all patients with the studied cancers based on current evidence.
• The early adoption of HDCT by some clinicians may reflect differing philosophical approaches to novel therapies.
• Further results from ongoing randomized trials are crucial to determine the definitive role of HDCT in cancer management.